Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
15.04.2025 08:57:26

EQS-Adhoc: Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Half Year Results/Quarter Results
Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25

15-Apr-2025 / 08:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25
 
Jena, April 15, 2025
In the second quarter of fiscal year 2024/25 ending March 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of around EUR 560 million (previous year: EUR 472.1 million), based on preliminary data, an increase of around 19%. This includes a contribution of around EUR 54 million from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), which has been consolidated for the first time since April 2024. Excluding this contribution, revenue growth would have amounted to around 7%. Earnings before interest, taxes and amortization on intangible assets from purchase price allocations (EBITA) reached around EUR 78 million (previous year: EUR 67.2 million). Earnings per share resulted in EUR 0.52 (previous year: EUR 0.52).

The increase in revenue and earnings in the second quarter of 2024/25 has been driven in particular by stronger than previously anticipated growth in the consumables business for refractive surgery in China.

After 6 months 2024/25, revenue reached around EUR 1,050 million (previous year: EUR 947.2 million) and EBITA reached EUR 114 million (previous year: EUR 113.2 million). Earnings per share came in at EUR 0.70 (previous year: EUR 0.94).

For fiscal year 2024/25, Carl Zeiss Meditec AG expects moderate revenue growth (against a previous year’s base of EUR 2,066.1 million) as well as a stable to slightly higher EBITA (against a previous year’s base of EUR 248.9 million). In light of current macro-economic and geopolitical uncertainties regarding the introduction of trade tariffs by the United States of America and incremental currency risks a more precise update to the forecast cannot currently be provided.

The half year report 2024/25 will be published on May 13, 2025.
 
 

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.med@zeiss.com

 

 

 

 

 

 

 

 

 



End of Inside Information

15-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2117766

 
End of Announcement EQS News Service

2117766  15-Apr-2025 CET/CEST

Analysen zu Carl Zeiss Meditec AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
16.04.25 Carl Zeiss Meditec Buy Hauck Aufhäuser Lampe Privatbank AG
16.04.25 Carl Zeiss Meditec Outperform Bernstein Research
16.04.25 Carl Zeiss Meditec Buy Goldman Sachs Group Inc.
15.04.25 Carl Zeiss Meditec Outperform Bernstein Research
15.04.25 Carl Zeiss Meditec Underweight JP Morgan Chase & Co.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien im BX Musterportfolio📈: Dollarama, Telekom & Waste Connections mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Dollarama
✅ Telekom
✅ Waste Connections

Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien im BX Musterportfolio📈: Dollarama, Telekom & Waste Connections im Check!

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’332.05 18.45 BFDS6U
Short 12’571.58 13.42 BKFSAU
Short 13’008.31 8.91 BVKSPU
SMI-Kurs: 11’942.05 25.04.2025 17:31:45
Long 11’360.00 19.78
Long 11’100.00 13.97
Long 10’570.78 8.75 SSPM6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}